Nachrichten zur Pfizer Inc. Aktie

Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?

…

Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?

Pfizers dividend yield is rising as the stock price is falling.…

Global Dyspepsia Drugs Market Size To Worth Exceed USD 14.7 Billion By 2033 | CAGR Of 4.46%

The Global Dyspepsia Drugs Market Size was Valued at USD 9.5 Billion in 2023 and the Worldwide Dyspepsia Drugs Market…

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the…

Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe?

…

Pfizer: Turning The Corner (Rating Upgrade)

…

How Much Will Pfizer Pay Out in Dividends This Year?

As one of the worlds largest drugmakers, Pfizer generates lots of cash it can share with investors.…

Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%

The Global Topical Wound Agents Market Size was valued at USD 1.9 Billion in 2023 and the Global Topical Wound…

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

PALM BEACH, Fla., May 24, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The pancreatic cancer…

Pfizer: Down To A Historically Low Valuation - Is It A Buy?

…

Global Systemic Aspergillosis and Systemic Candidiasis Research Report 2024-2030 Featuring Sanofi, Cipla, Pfizer, GSK, Novartis, Bayer, Merck, F. Hoffmann-La Roche, Abbott, Gilead Sciences

Dublin, May 24, 2024 (GLOBE NEWSWIRE) -- The "Global Systemic Aspergillosis and Systemic Candidiasis Market (2024 Edition): Analysis…

Pharma Stock Roundup: AZNs 2030 Sales Target, PFEs New Cost Cut Plan & More

AstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase…

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts,…

Pfizer: Kostensenkungsprogramm positiv für die Aktie - Aktienanalyse

Toronto (www.aktiencheck.de) - Pfizer-Aktienanalyse von BMO Capital Markets: Evan Seigerman, Analyst von BMO Capital Markets, stuft die Aktie von Pfizer Inc.…

13:48: Moderna: Intakter Trend versus Analysten-Skepsis

Ein Teilerfolg im Rechtsstreit mit Pfizer und BioNTech um den Impfstoff Covid-19 hat die Aktie des amerikanischen Biotechnologieunternehmens Moderna in…

Pfizer: Kostenaktualisierung ist positiv - Aktienanalyse

New York (www.aktiencheck.de) - Pfizer-Aktienanalyse von Morgan Stanley: Die Analysten von Morgan Stanley stufen die Aktie von Pfizer Inc. (ISIN: US7170811035,…

Vaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccines By Investing.com

Vaccine stocks gain, Moderna and Pfizer in talks with the US on bird flu vaccines…

Pharmariese setzt neue Segel: Pfizers neues Sparprogramm und Vogelgrippewelle treiben die Aktie an

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines…

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

This is the second cost-reduction program undertaken by Pfizer (PFE) in the past year. The first phase of this program…

Pfizer, Moderna in talks with HHS over avian flu vaccine: report (update)

…

The Prognosis For Pfizer

…

Pfizer: Kurz nach Bekanntwerden der Nachricht hat die Aktie zugelegt! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…

BioNTech-Partner Pfizer: Einsparungen in Milliardenhöhe

Der US-Pharmakonzern Pfizer will bis Ende 2027 rund 1,5 Milliarden Dollar einsparen. Erste Effekte dürften ab dem kommenden Jahr realisiert…

Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts

Pfizer is also carrying out another $4 billion cost-cutting effort, which it announced last year as demand for its Covid…

Pfizer-Aktie gewinnt: Pfizer kündigt Einsparzielt bis Ende 2027 im Milliardenwert an

Der US-Pharmakonzern Pfizer will bis Ende 2027 rund 1,5 Milliarden US-Dollar (1,38 Mrd Euro) einsparen.…

Pfizer to Cut Costs in Multi-Year Effort

…

Pfizer will bis Ende 2027 rund 1,5 Milliarden US-Dollar einsparen

NEW YORK (dpa-AFX) - Der US-Pharmakonzern Pfizer will bis Ende 2027 rund 1,5 Milliarden US-Dollar (1,38 Mrd Euro) einsparen.…

Pfizer will bis Ende 2027 rund 1,5 Milliarden US-Dollar einsparen

NEW YORK (dpa-AFX) - Der US-Pharmakonzern Pfizer will bis Ende 2027 rund 1,5 Milliarden US-Dollar…

Pfizer targets $1.5 billion in savings by 2027 as it streamlines operations By Reuters

Pfizer targets $1.5 billion in savings by 2027 as it streamlines operations…

Pfizer rolls out another cost-cutting program, sets $1.5 billion target by 2027

…

Pfizer: Seit dem letzten Quartalsbericht ist wieder etwas Hoffnung spürbar - Kaufen! Aktienanalyse

Wien (www.aktiencheck.de) - Pfizer-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), rät in…

Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs

…

Billionaires Are Buying Beaten-Down Pfizer Stock Hand Over Fist. Should You Follow Their Lead?

Pfizer stock lost nearly half its value over the past couple of years, but some of the worlds most successful…

Billionaires Are Buying Beaten-Down Pfizer Stock Hand Over Fist. Should You Follow Their Lead? @themotleyfool #stocks $PFE

Pfizer stock lost nearly half its value over the past couple of years, but some of the worlds most successful…

Antiandrogens Market Insights and Projections to 2030: An $8.7 Billion Landscape Dominated by Pfizer, Astellas Pharma, Roche, AstraZeneca, and Abbott Labs

Dublin, May 21, 2024 (GLOBE NEWSWIRE) -- The "Antiandrogens Market Report: Trends, Forecast and Competitive Analysis to 2030"…

Ryanair meldet Rekordjahresgewinn - JPMorgan plant keine großen Aktienrückkaufprogramme

Wien (www.aktiencheck.de) - Moderna (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF, NASDAQ-Symbol: MRNA) (+6,1%) konnte gestern von der Entscheidung des Europäischen…

Moderna mit Punktgewinn gegen BioNTech: Aktie Top-Gewinner im Nasdaq 100

Die Aktie von Moderna führt am heutigen Montag die Gewinnerliste im Nasdaq 100 klar an. Das Papier gewinnt mehr als…

[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Pfizer wins cancer drug patent case against AstraZeneca

…

Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?

Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year.…

Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead? @themotleyfool #stocks $PFE $WBA

Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year.…

European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech

…

GSK verkauft Haleon-Beteiligung im Milliardenwert - Aktien in Rot

Der britische Pharmakonzern hat damit die schrittweise Veräußerung von Anteilen an dem Unternehmen, das 2019 aus einem Joint Venture mit…

Pfizer: Potential Double-Digit Upside Combined With High Dividend Yield

…

Global Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5%

The Global Oral Transmucosal Drugs Market Size was Valued at USD 33.2 Billion in 2023 and the Worldwide Oral Transmucosal…

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months),…

dpa-AFX ProFeed